Contribute Try STAT+ Today

Before Covid-19 came along, there was nothing that loomed larger in biotech than aducanumab, Biogen’s controversial treatment for Alzheimer’s disease.

On Nov. 6, the Food and Drug Administration is convening a meeting of outside experts to review the data from two Phase 3 clinical trials of aducanumab. At the end of the meeting, this panel of experts is expected to vote on whether the drug should be approved, or not. The FDA isn’t required to follow the panel’s recommendation, but it will surely factor heavily into whatever decision the agency ultimately makes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy